immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. It operates through the Therapeutic antibody and Bio CRO businesses. Its offers antibodies and detection kits. The company was founded by Carl Erik Mathias Uhlén and Jong-Seo Lee on June 25, 2010 and is headquartered in Seoul, South Korea.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. It operates in the Commercial and Research segments. The Commercial segment involves the sales, marketing, laboratory, and support to run the commercial businesses worldwide. The Research segment engages in the research and development of diagnostic and prognostic products for human cancer. The company was founded on February 27, 2001 and is headquartered in Dunedin, New Zealand.

Genomictree Inc. is a company based out of South Korea.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research and development, manufacture, distribution, and retail of pharmaceutical products. The company was founded on January 18, 1994 and is headquartered in Shanghai, China.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

Shanghai Genechem Co., Ltd. engages in the research and development of gene therapy, cell therapy, and new gene targeting of antibody drugs. It also provides gene targeting verification, new drug development, and medical test services. The company was founded by Yue Qiong Cao on August 23, 2002 and is headquartered in Shanghai, China.

Part of University of Adelaide, Adelaide Research & Innovation Pty Ltd. is an Australian company located in Adelaide. The firm provides analytical research services. Robert Chalmers is the current CEO of the firm.

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. It also offers acetaldehyde binding products, monoclonal antibodies, and instruments. The company was founded by Osmo Suovaniemi in 1988 and is headquartered in Helsinki, Finland.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.